Sanofi-Aventis Set To Appeal Invalidation Of Drug Patent In China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - In the latest twist in one of the most closely followed pharmaceutical patent disputes ever in China, an executive at Sanofi-Aventis said the company will appeal the recent invalidation of its patent for an injectable anti-cancer drug in Beijing